Verve Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Verve Therapeutics, a clinical-stage biotechnology firm, will have its CEO, Sekar Kathiresan, present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 4:30 p.m. PT in San Francisco. The live presentation will be accessible via webcast, archived for 30 days. Verve focuses on innovative gene editing therapies for cardiovascular disease, notably through programs VERVE-101 and VERVE-201, aimed at lowering LDL cholesterol levels to combat heart disease.

BOSTON, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present at the 41^st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 4:30 p.m. PT in San Francisco.

A live webcast will be available in the investor section of the company's website at www.vervetx.com. The webcast will be archived for 30 days following the presentation.

About Verve Therapeutics 
Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two programs – VERVE-101 and VERVE-201 – target genes that have been extensively validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease, in order to durably reduce blood LDL-C levels. VERVE-101 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat atherosclerotic cardiovascular disease (ASCVD) patients not at goal on oral therapy. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed in homozygous familial hypercholesterolemia (HoFH) and ultimately to treat patients with ASCVD who have not achieved goal LDL-C with oral therapy and a PCSK9 inhibitor. For more information, please visit www.VerveTx.com

Investor Contact
Jen Robinson
Verve Therapeutics, Inc.
jrobinson@vervetx.com

Media Contact
Ashlea Kosikowski
1AB
ashlea@1abmedia.com

FAQ

What is the date and time of Verve Therapeutics' presentation at the J.P. Morgan Healthcare Conference?

Verve Therapeutics will present on January 9, 2023, at 4:30 p.m. PT.

Where can I watch Verve Therapeutics' presentation from the J.P. Morgan Healthcare Conference?

The presentation will be available via live webcast on Verve Therapeutics' investor website and archived for 30 days.

What are the main programs being developed by Verve Therapeutics?

The main programs are VERVE-101 and VERVE-201, which target genes to lower LDL cholesterol levels.

What is the focus of Verve Therapeutics' research?

Verve Therapeutics focuses on gene editing medicines for the treatment of cardiovascular disease.

What is the significance of the J.P. Morgan Healthcare Conference for Verve Therapeutics?

The J.P. Morgan Healthcare Conference is a significant event for Verve Therapeutics to present its innovative gene editing approaches to investors and stakeholders.